Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies

What happened: Kos Biotechnology Partners announced a strategic investment in Golden Age Health through its inaugural fund, Kos BioVentures. Kos Managing Partner Alex Tzoukas will join the Golden Age Health Board of Directors. Key numbers: Kos manages $125 million in assets. Golden Age Health was co-founded in 2023. The announcement is dated Oct. 26, 2026. Why it matters: The investment is intended to expand Golden Age Health's commercial presence and portfolio in Greater China and Asia-Pacific and to accelerate cross-border flow of biotech innovation between Western markets and Asia. Market: +0.6% today ($252.26), +41.9% YTD, 0.9x vol — as of 22:15 UTC Verified: Q3_2026 (Oct 28) revenue $2.6B vs $2.6B est; next print ~Jan 27

Kos Biotechnology Partners announced a strategic investment in Golden Age Health through its inaugural fund, Kos BioVentures. Kos Managing Partner Alex Tzoukas will join the Golden Age Health Board of Directors.

The investment is intended to expand Golden Age Health's commercial presence and portfolio in Greater China and Asia-Pacific and to accelerate cross-border flow of biotech innovation between Western markets and Asia. Market: +0.6% today ($252.26), +41.9% YTD, 0.9x vol — as of 22:15 UTC Verified: Q3_2026 (Oct 28) revenue $2.6B vs $2.6B est; next print ~Jan 27